Cargando…

The pathophysiology of Wilson’s disease visualized: A human (64)Cu PET study

BACKGROUND AND AIMS: Wilson’s disease (WD) is a genetic disease with systemic accumulation of copper that leads to symptoms from the liver and brain. However, the underlying defects in copper transport kinetics are only partly understood. We sought to quantify hepatic copper turnover in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandahl, Thomas Damgaard, Gormsen, Lars C., Kjærgaard, Kristoffer, Vendelbo, Mikkel Holm, Munk, Ditte Emilie, Munk, Ole Lajord, Bender, Dirk, Keiding, Susanne, Vase, Karina H., Frisch, Kim, Vilstrup, Hendrik, Ott, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305563/
https://www.ncbi.nlm.nih.gov/pubmed/34773664
http://dx.doi.org/10.1002/hep.32238
Descripción
Sumario:BACKGROUND AND AIMS: Wilson’s disease (WD) is a genetic disease with systemic accumulation of copper that leads to symptoms from the liver and brain. However, the underlying defects in copper transport kinetics are only partly understood. We sought to quantify hepatic copper turnover in patients with WD compared with heterozygote and control subjects using PET with copper‐64 ((64)Cu) as a tracer. Furthermore, we assessed the diagnostic potential of the method. APPROACH AND RESULTS: Nine patients with WD, 5 healthy heterozygote subjects, and 8 healthy controls were injected with an i.v. bolus of (64)Cu followed by a 90‐min dynamic PET scan of the liver and static whole‐body PET/CT scans after 1.5, 6, and 20 h. Blood (64)Cu concentrations were measured in parallel. Hepatic copper retention and redistribution were evaluated by standardized uptake values (SUVs). At 90 min, hepatic SUVs were similar in the three groups. In contrast, at 20 h postinjection, the SUV in WD patients (mean ± SEM, 31 ± 4) was higher than in heterozygotes (24 ± 3) and controls (21 ± 4; p < 0.001). An SUV‐ratio of hepatic (64)Cu concentration at 20 and 1.5 h completely discriminated between WD patients and control groups (p < 0.0001; ANOVA). By Patlak analysis of the initial 90 min of the PET scan, the steady‐state hepatic clearance of (64)Cu was estimated to be slightly lower in patients with WD than in controls (p = 0.04). CONCLUSIONS: (64)Cu PET imaging enables visualization and quantification of the hepatic copper retention characteristic for WD patients. This method represents a valuable tool for future studies of WD pathophysiology, and may assist the development of therapies, and accurate diagnosis.